BR9815580A - Vaccine composition, processes to generate an anti-idiotype response in a subject, to treat or prevent cancer, to treat or prevent an infectious disease, to prepare a first immunoglobulin molecule, and, first immunoglobulin molecule - Google Patents

Vaccine composition, processes to generate an anti-idiotype response in a subject, to treat or prevent cancer, to treat or prevent an infectious disease, to prepare a first immunoglobulin molecule, and, first immunoglobulin molecule

Info

Publication number
BR9815580A
BR9815580A BR9815580-6A BR9815580A BR9815580A BR 9815580 A BR9815580 A BR 9815580A BR 9815580 A BR9815580 A BR 9815580A BR 9815580 A BR9815580 A BR 9815580A
Authority
BR
Brazil
Prior art keywords
treat
prevent
immunoglobulin molecule
processes
generate
Prior art date
Application number
BR9815580-6A
Other languages
Portuguese (pt)
Inventor
Ronald M Burch
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BR9815580A publication Critical patent/BR9815580A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"COMPOSIçãO DE VACINA, PROCESSOS PARA GERAR UMA RESPOSTA DE ANTI-IDIóTIPO EM UM SUJEITO, PARA TRATAR OU PREVENIR CâNCER, PARA TRATAR OU PREVENIR UMA DOENçA INFECCIOSA, PARA PREPARAR UMA PRIMEIRA MOLéCULA DE IMUNOGLOBULINA, E, PRIMEIRA MOLéCULA DE IMUNOGLOBULINA". A invenção refere-se às moléculas de imunoglobulina modificada nas quais um ou mais resíduos de região variável que formam pontes de dissulfeto de intracadeias são substituídos por resíduos de aminoácido que não contêm grupos sulfidrila, de tal modo que não possa ser formada a ponte de dissulfeto de intracadeia. Tais moléculas de imunoglobulina apresentam uma capacidade aumentada de gerar uma resposta de anti-idiótipo. A invenção proporciona adicionalmente os processos para prevenção e tratamento de câncer e/ou de doenças infecciosas usando as imunoglobulinas modificadas da invenção."VACCINE COMPOSITION, PROCESSES TO GENERATE AN ANTI-IDIOTYPE RESPONSE IN A SUBJECT, TO TREAT OR PREVENT CANCER, TO TREAT OR PREVENT AN INFECTIOUS DISEASE, TO PREPARE A FIRST IMMUNOGLOBULINE MOLECULE, AND, IMMOLCULINE, AND IMMOLCULINE. The invention relates to modified immunoglobulin molecules in which one or more residues of variable region that form intrachain disulfide bridges are replaced by amino acid residues that do not contain sulfhydryl groups, so that the disulfide bridge cannot be formed of intrachain. Such immunoglobulin molecules have an increased ability to generate an anti-idiotype response. The invention further provides the processes for preventing and treating cancer and / or infectious diseases using the modified immunoglobulins of the invention.

BR9815580-6A 1997-11-14 1998-11-13 Vaccine composition, processes to generate an anti-idiotype response in a subject, to treat or prevent cancer, to treat or prevent an infectious disease, to prepare a first immunoglobulin molecule, and, first immunoglobulin molecule BR9815580A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6571697P 1997-11-14 1997-11-14
US8140398P 1998-04-10 1998-04-10
PCT/US1998/024303 WO1999025379A1 (en) 1997-11-14 1998-11-13 Modified antibodies with enhanced ability to elicit an anti-idiotype response

Publications (1)

Publication Number Publication Date
BR9815580A true BR9815580A (en) 2002-01-29

Family

ID=26745908

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9815580-6A BR9815580A (en) 1997-11-14 1998-11-13 Vaccine composition, processes to generate an anti-idiotype response in a subject, to treat or prevent cancer, to treat or prevent an infectious disease, to prepare a first immunoglobulin molecule, and, first immunoglobulin molecule
BR9815289-0A BR9815289A (en) 1997-11-14 1998-11-13 Modified immunoglobulin, molecule, isolated nucleic acid, cell containing the same, recombinant non-human animal, pharmaceutical composition, vaccine composition, processes for identifying or measuring or detecting a cancer antigen, an antigen from an infectious disease agent, a ligand, and a receptor in a sample. to be tested, kits for detecting a cancer antigen, an infectious disease agent antigen, a cell receptor for an infectious disease agent, a ligand, and a cancer antigen, diagnostic processes or testing for the presence of or a predisposition for the development of a cancer by the increased presence of a cancer antigen, and for the presence of an infectious disease, treatment or prevention of a cancer by the presence of a cancer antigen, of an infectious disease typified by the presence of an antigen infectious disease agent, and a disease caused by an infectious disease agent that binds to a cell receptor, processes for modulating activity of a first member of a binding pair, process for producing a modified immunoglobulin, process for producing a modified immunoglobulin nucleic acid, and, isolated nucleic acid

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9815289-0A BR9815289A (en) 1997-11-14 1998-11-13 Modified immunoglobulin, molecule, isolated nucleic acid, cell containing the same, recombinant non-human animal, pharmaceutical composition, vaccine composition, processes for identifying or measuring or detecting a cancer antigen, an antigen from an infectious disease agent, a ligand, and a receptor in a sample. to be tested, kits for detecting a cancer antigen, an infectious disease agent antigen, a cell receptor for an infectious disease agent, a ligand, and a cancer antigen, diagnostic processes or testing for the presence of or a predisposition for the development of a cancer by the increased presence of a cancer antigen, and for the presence of an infectious disease, treatment or prevention of a cancer by the presence of a cancer antigen, of an infectious disease typified by the presence of an antigen infectious disease agent, and a disease caused by an infectious disease agent that binds to a cell receptor, processes for modulating activity of a first member of a binding pair, process for producing a modified immunoglobulin, process for producing a modified immunoglobulin nucleic acid, and, isolated nucleic acid

Country Status (9)

Country Link
EP (2) EP1032420A4 (en)
JP (2) JP2002507544A (en)
KR (2) KR20010015817A (en)
CN (2) CN1327388A (en)
AU (2) AU763029B2 (en)
BR (2) BR9815580A (en)
CA (2) CA2310269A1 (en)
IL (2) IL136113A0 (en)
WO (2) WO1999025379A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2350917A1 (en) * 1998-11-13 2000-05-25 Euro-Celtique, S.A. Contraceptive antibody vaccines
PT1092779E (en) * 1999-10-11 2010-01-19 Pasteur Institut Lentiviral vectors for the preparation of immunotherapeutical compositions
WO2001088159A2 (en) * 2000-05-16 2001-11-22 Euro-Celtique S.A. Cd28 synthebody for the modulation of immune responses
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ATE414720T1 (en) 2000-12-05 2008-12-15 Alexion Pharma Inc RATIONALLY DESIGNED ANTIBODIES
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
WO2002078613A2 (en) * 2001-04-02 2002-10-10 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
AU2002365926A1 (en) * 2001-10-25 2003-09-02 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
EP1938834B1 (en) * 2002-04-09 2012-04-25 The Curators Of The University Of Missouri Treatment of type 1 diabetes before and after expression of predisposition markers
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
CA2499300A1 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
WO2005021595A1 (en) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
CN1938428A (en) 2003-11-12 2007-03-28 先灵公司 Plasmid system for multigene expression
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
CA2558813A1 (en) * 2004-03-09 2005-09-15 Kyoto University Pharmaceutical composition comprising cxcr3 inhibitor
ATE493442T1 (en) 2004-12-03 2011-01-15 Schering Corp BIOLOGICAL MARKERS FOR PRE-SELECTION OF PATIENTS FOR ANTI-IGF1R THERAPY
ZA200901165B (en) * 2006-08-28 2010-06-30 Kyowa Hakko Kirin Co Ltd Antagonistic human light-specific human monoclonal antibodies
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
WO2009114585A1 (en) * 2008-03-12 2009-09-17 Imclone Llc Anti-tyrp1 antibodies
EP2799453B1 (en) * 2009-04-29 2019-04-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ERG2 monoclonal antibodies and their therapeutic use
CN102816240B (en) * 2011-03-08 2014-02-12 中国人民解放军第三军医大学第二附属医院 Fusion protein and fusion protein expression vector thereof
EP2714083A4 (en) * 2011-05-27 2015-03-04 Fox Chase Cancer Ct Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
JP6121436B2 (en) * 2011-11-23 2017-04-26 バイオベン・3・リミテッドBioven 3 Limited Recombinant proteins and their therapeutic uses
JP5437525B1 (en) 2012-12-28 2014-03-12 株式会社ナード研究所 Tyrosine derivative and method for producing tyrosine derivative
US20160206732A1 (en) * 2013-05-14 2016-07-21 Shanghai Hycharm Inc. Epitope vaccine for low immunogenic protein and preparing method and usage thereof
CN103275914B (en) * 2013-06-03 2015-04-01 中国人民解放军军事医学科学院微生物流行病研究所 Bacterial ghost presenting protective antigens and application thereof
CN105263953B (en) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 Porcine parvovirus 5A, methods of use, and vaccines
CA2949174A1 (en) * 2014-05-19 2015-11-26 Helsingin Yliopisto Modified adenoviruses for cancer vaccines development
CN105693859B (en) * 2016-03-22 2019-06-21 苏州莱泰生物科技有限公司 Anti-human G2A monoclonal antibody and the kit for detecting human macrophage G2A expression quantity
CN111978382B (en) * 2020-09-03 2022-03-04 吉林大学第一医院 Preparation method and application of recombinant protein of Sporothrix globosum Gp70
CN112646029B (en) * 2020-12-30 2022-07-29 深圳清华大学研究院 Antibody of mature brain-derived neurotrophic factor, application thereof and diagnostic kit
CN115856296B (en) * 2022-12-16 2023-07-25 华北理工大学 Monoclonal antibody for resisting shigella and application thereof in detection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
ATE130765T1 (en) * 1989-02-24 1995-12-15 Univ California GENETICALLY MODIFIED IMMUNOGLOBULINS.
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
JPH09503901A (en) * 1992-11-16 1997-04-22 キャンサー リサーチ ファンド オブ コントラ コスタ Peptides and antisense peptides with broad neoplastic specificity
WO1994014848A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
WO1994014847A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
US5624904A (en) * 1993-11-17 1997-04-29 Massachusetts Institute Of Technology Method for treating gram positive septicemia

Also Published As

Publication number Publication date
JP2001526021A (en) 2001-12-18
IL136114A0 (en) 2001-05-20
AU2003252902A1 (en) 2003-11-06
EP1032420A4 (en) 2004-09-15
AU1459899A (en) 1999-06-07
IL136113A0 (en) 2001-05-20
EP1030684A1 (en) 2000-08-30
AU737457B2 (en) 2001-08-23
CA2309990A1 (en) 1999-05-27
EP1030684A4 (en) 2004-09-15
CN1327388A (en) 2001-12-19
WO1999025378A9 (en) 1999-08-12
KR20010015817A (en) 2001-02-26
AU763029B2 (en) 2003-07-10
CA2310269A1 (en) 1999-05-27
WO1999025378A1 (en) 1999-05-27
CN1294517A (en) 2001-05-09
JP2002507544A (en) 2002-03-12
BR9815289A (en) 2001-12-26
KR20010015818A (en) 2001-02-26
AU1459799A (en) 1999-06-07
WO1999025379A1 (en) 1999-05-27
EP1032420A1 (en) 2000-09-06

Similar Documents

Publication Publication Date Title
BR9815580A (en) Vaccine composition, processes to generate an anti-idiotype response in a subject, to treat or prevent cancer, to treat or prevent an infectious disease, to prepare a first immunoglobulin molecule, and, first immunoglobulin molecule
DE69027865D1 (en) COMPOSITIONS containing omega conotoxin peptide derivatives and their use for the treatment of ischemic-like neuronal damage
BR9910023A (en) Polyol conjugates-ifn-beta
DE69429527T2 (en) INHIBITORS OF BETA AMYLOID PROTEIN PRODUCTION
DK1002064T3 (en) Modified polypeptide
BRPI9715334B8 (en) estrogenic agents and pharmaceutical composition comprising them.
EA199901063A1 (en) PIPERAZINE DERIVATIVES AND THEIR APPLICATION AS ANTI-INFLAMMATORY AGENTS
BR9806925A (en) Oil-in-water emulsion, use of an oil-in-water emulsion, cosmetic and / or dermatological composition, cosmetic treatment process and use of 1,3,5-triazine derivatives
NO20053920L (en) Preparation and treatment of demyelination diseases and paralysis in the administration of remyelination agents.
AR003457A1 (en) AN ANTIMICROBIAL HAIR TREATMENT COMPOSITION
BR9907995A (en) Immunological methods to modulate myostatin in vertebrate subjects
CY1111912T1 (en) METHOD OF RESTRICTING OSTEOKLASTS ACTIVITY
DE69230690D1 (en) CEREAL EXTRACTS
AR018535A1 (en) CONJUGATES OF ONE OR MORE FRAGMENTS OF ANTIBODIES COVALENTLY UNITED TO ONE OR MORE MOLECULES OF NON-PROTEIC POLYMER, A COMPOSITION THAT INCLUDES THEMSELVES AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT TO TREAT AN INFLAMMATORY DISORDER.
BR9811099A (en) Urokinase inhibitors
BRPI0516363A (en) hair care composition and process for preparing a hair composition
ES2135470T3 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS THAT USE IBOBUTYRAMIDE TO TREAT BETAGLOBIN DISORDERS.
BR9508467A (en) Somatostatin receptor binding peptide matter composition pharmaceutical composition and process for performing radiosotope-guided surgery or a radiodiagnostic or radiotherapeutic procedure and for alleviating a somatostetin-related disease in an animal
PT965323E (en) AGENTS AND THEIR COATING COMPOSITIONS FOR THE TREATMENT OF HAIR CONTAINING DEVELOPED FUCANO SULPHATES
ES549115A0 (en) PROCEDURE FOR PRODUCING PREPARATIONS TO TREAT HEMOPHILIA PATIENTS TO INHIBITORS
ATE78397T1 (en) USE OF P-CHLOROPHENOXYACETATE OF N,NDIMETHYLBIGUANIDE FOR THE TREATMENT OF NEUROPATHIES AND NERVE DEGENERATION.
EE200100125A (en) TAN-1057 derivatives
EA200000242A1 (en) FANHINONA APPLICATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ATE251631T1 (en) DIPOHOSPHONIC ACID SALTS FOR THE TREATMENT OF OSTEOPOROSIS
ATE151774T1 (en) CYCLOPENTANPERHYDROPHENANTHRENE-17-BETA-(3-FURYL - 3-DERIVATIVES AND PHARMACEUTICAL PREPARATIONS THEREOF FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.